The Leidos Biomedical Research, Inc. rsquo;s, staff of scientific, technical, and support professionals conduct basic and applied research in cancer and AIDS. It operates and manages the federal government rsquo;s only vaccine manufacturing facilities (Vaccine Pilot Plant [VPP] and Biopharmaceutical Development Program [BDP]) and runs the high-performance Advanced Biomedical Computing Center. It also operates the Frederick National Laboratory for Cancer Research, a Federally Funded Research and Development Center focused on cancer and AIDS research.
The Leidos Biomedical Research Group rsquo;s Biospecimen Research Group (BRG) supports projects across the National Cancer Institute (NCI) that require expertise in the infrastructure needed to support the collection and use of human biospecimens for cancer research as well as other areas where scientific knowledge of advanced computing and/or scientific technologies is required.
The NCI rsquo;s Biorepositories and Biospecimen Research Branch (BBRB) and the Leidos Biomed BRG are jointly responsible for developing a common biorepository infrastructure that promotes resource sharing and team science, to facilitate multi-institutional, high-throughput genomic and proteomic studies. Currently, Leidos Biomed is supporting the NCI Cancer Moonshot℠ Biobank program. The NCI rsquo;s Cancer Moonshot℠ program is intended to accelerate cancer research in key strategic areas. The strategic areas were deliberated and identified by experts in the cancer research community convened in 2016 through a ldquo;Blue Ribbon Panel rdquo; (BRP). The BRP produced a set of recommendations that are now publicly available (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel). The strategic areas addressed in the BRP recommendations have in common two core elements: (1) critical scientific and medical questions, the answers to which could rapidly accelerate progress in cancer research, and (2) the need for nationwide participation by a diverse group of research participants who have agreed to share their biospecimens and/or derived data to contribute to progress in cancer research. The latter element, an engaged and diverse research participant population and their donations of biospecimens and data, will be critical to accelerating research progress and is the subject of the project for which Leidos Biomed is seeking an experienced Quality Assurance Manager. The Cancer Moonshot℠ Biobank will provide a networked biospecimen resource that will serve the goal of the Cancer Moonshot℠ to accelerate research progress in cancer.
For the Moonshot℠ Biobank Program, up to 2,000 longitudinal cases from patients with 10 different cancer types will be collected, to include tissue resections, core biopsies, fine needle aspirates, and blood. The biospecimens will be utilized by researchers studying the mechanisms of drug resistance and sensitivity and other important cancer research questions. Subcontracts with up to 100 different cancer centers will be put in place to enable the engagement and participation of physicians and patients, including minority and underserved as well as adolescent and young adult cancer patients. Tumor molecular characterization tests will be performed as part of the program to help inform patient treatment decisions. Some tissues will be sent for Patient Derived Xenograft (PDX) model development at the Frederick National Laboratory for Cancer Research. A central Biospecimen Core Resource will be engaged for biospecimen processing and storage. Project data will be uploaded to the NCI Genomic Data Commons to enable data analysis by the broader research community.
The BRG also supports work being performed for the NCI rsquo;s Center for Strategic Scientific Initiatives (CSSI), specifically the Clinical Proteomic Tumor Analysis Consortium (CPTAC), a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer with the primary goal to improve the ability to diagnose, treat, and prevent cancer by systematically identifying proteins that derive from alterations in cancer genomes and related biological processes, and provide this data with accompanying assays and protocols to the public.
The Quality Manager II will:
To be considered for this position, you must minimally meet the knowledge, skills, and abilities listed below:
Candidates with these desired skills will be given preferential consideration: